Journal profile · CARDIAC & CARDIOVASCULAR SYSTEMS
Cardiovascular Revascularization Medicine
ISSN 1553-8389 · eISSN 1878-0938 · Elsevier
Cardiovascular Revascularization Medicine: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.3 (journal website); hybrid open access; APC about USD 3,490; median 38 days to acceptance (84 articles, last 24 months); 272 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Cardiovascular Revascularization Medicine is published by Elsevier and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Coronary Interventions and Diagnostics, Cardiac Valve Diseases and Treatments and Cardiac Imaging and Diagnostics, together about 38.5% of its articles. Its main subfields are Cardiology and Cardiovascular Medicine and Pulmonary and Respiratory Medicine. (generated from OpenAlex topic counts and CAS ranking data)
including Molecular Interventions Cardiovascular Revascularization Medicine (CRM) is an international, English-language, multidisciplinary, peer-reviewed journal that publishes original laboratory and clinical investigations related to revascularization therapies in cardiovascular medicine. CRM publishes 12 regular print issues and a supplemental issue each year.The journal is indexed on Index Medicus and MEDLINE®/PubMed®.The journal's location in Washington, DC, gives it an advantage in reporting on regulatory issues as they pertain to interventional cardiology and structural heart disease. The journal is read by cardiologists, interventional cardiologists, structural heart interventionalists, vascular physicians, healthcare regulators, industry, fellows in training, and innovators around the globe.CRM is also the official journal of the Cardiovascular Research Technologies (CRT) meeting, a premier event that brings together about 3,000 interventional cardiologists annually to discuss cutting-edge research and innovations. Attendees are encouraged to submit papers based on abstracts, interesting cases, late-breaking trials, and innovations presented at the meeting that impact interventional cardiologists' practice. The journal structures its content to reflect topics based on each track of the CRT meeting: Complex Coronary, Valve and Structural, Endovascular, Imaging and Physiology, Atherosclerosis, Cardiogenic Shock, Technology and Innovation, Regulatory and Healthcare Policy, and Innovations.CRM publishes articles related to preclinical and clinical work, including pharmacological interventions, and restenosis management; and treatment, including experiments conducted in human subjects, laboratory animals, and in vitro. Specific areas of interest include percutaneous angioplasty in coronary and peripheral arteries, intervention in structural heart disease, cardiovascular surgery, congenital heart disease, coronary heart disease, genetics and translational science, health services and outcomes research, invasive imaging, regulatory and health policy, technology and innovation, and vascular medicine.The journal's nearest competitors are JACC: Cardiovascular Interventions, Circulation: Cardiovascular Interventions, and EuroIntervention.CRM will consider all articles describing clinical trials and translational research (i.e., those that unite the clinic with the laboratory). The journal publishes original articles, research letters, reviews, editorials, and special features. Original articles that address any aspect of cardiovascular revascularization or structural intervention are invited. Letters to the editor, trial design papers, and interesting images are encouraged. The journal's peer-review process is single-blind.
From the journal's Aims & Scope
Research area (LetPub): CARDIAC & CARDIOVASCULAR SYSTEMS
Editor-in-chief Ron WaksmanPublisher website
Editorial board by country: 2 in mainland China (about 1%); most named United States 176, Germany 14, Italy 13, United Kingdom 8, Netherlands 7 (247 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Coronary Interventions and DiagnosticsMedicine18%
- Cardiac Valve Diseases and TreatmentsMedicine10.5%
- Cardiac Imaging and DiagnosticsMedicine9.9%
- Acute Myocardial Infarction ResearchMedicine7.3%
- Peripheral Artery Disease ManagementMedicine5.9%
- Vascular Procedures and ComplicationsMedicine5.2%
- Cerebrovascular and Carotid Artery DiseasesMedicine3.5%
- Aortic Disease and Treatment ApproachesMedicine3.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Cardiac & Cardiovascular Systems | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Cardiac & Cardiovascular Systems | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PubMedPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 2.3Publisher website ·
- CiteScore 2026-06
- 4LetPub ·
- CiteScore (publisher)
- 4Publisher website ·
- SJR 2026-06
- 0.68LetPub ·
- SNIP 2026-06
- 0.85LetPub ·
- h-index
- 56OpenAlex ·
- i10-index
- 938OpenAlex ·
- 2-year mean citedness
- 1.38OpenAlex ·
- Self-citation rate
- 8.7%LetPub ·
- Share of gold OA articles
- 18.46%LetPub ·
Volume
- Articles per year
- 174LetPub ·
Articles by year OpenAlex count · 5,391 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 173 | 15 | 26 |
| 2025 | 272 | 54 | 432 |
| 2024 | 465 | 51 | 801 |
| 2023 | 562 | 75 | 1,060 |
| 2022 | 574 | 65 | 1,283 |
| 2021 | 437 | 71 | 2,424 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
38 daysMedian, submission to acceptance · P25–P75 26 days – 62 days
- Acceptance to online
- median 3 days (84 articles)
- Submission to online
- median 44 days
- Sample
- 84 articles with submission and acceptance dates (605 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to first decision
- 4 daysPublisher website ·
- First decision after review
- 28 daysPublisher website ·
- Submission to acceptance
- 37 daysPublisher website ·
- Acceptance to publication
- 3 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,490 / EUR 3,260 / GBP 2,790 / JPY 432,860 | — | — | |
| Publisher website | USD 3,440 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare1 items from the author guidelines
- Abstract
- ≤ 250 words
Article types accepted3
- case reportsCase ReportsLength not stated
- editorialsEditorialsLength not stated
- letters to the editorLetters to the EditorLength not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- ISSN
- 1553-8389
- Electronic ISSN
- 1878-0938
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Cardiovascular Revascularization Medicine
What CAS zone is Cardiovascular Revascularization Medicine in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cardiovascular Revascularization Medicine is in Zone 4 of Medicine, and in Zone 4 of the minor category Cardiac & Cardiovascular Systems. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cardiovascular Revascularization Medicine?
The journal's website gives an impact factor of 2.3; this is the journal's own figure, as LetPub lists none for it; CiteScore 4, h-index 56.
How long does peer review take at Cardiovascular Revascularization Medicine?
Based on the dates recorded on 84 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 38 days (interquartile range 26–62 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Cardiovascular Revascularization Medicine based?
Of the 247 board members whose country the journal's board page names, 2 (about 1%) are in mainland China; the countries named most often are United States (176), Germany (14) and Italy (13). Counted from the institutions listed on the board page; for reference only.
Which databases index Cardiovascular Revascularization Medicine?
According to LetPub and DOAJ records, Cardiovascular Revascularization Medicine is indexed in ESCI and Scopus. The journal's website also lists PubMed; that list has not been checked against each database.
Is Cardiovascular Revascularization Medicine open access, and what is the APC?
Cardiovascular Revascularization Medicine is a hybrid journal. For open-access publication: APC about USD 3,490.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .